Speaker illustration

Doctor Anders Nissen Bonde

Gentofte University Hospital, Gentofte (Denmark)

Men who live alone have poor anticoagulation control: results from Danish registries.

Event: ESC CONGRESS 2019

Topic: Oral Anticoagulation

Session: Atrial fibrillation and oral anticoagulation 3

Thumbnail

High facility preference for rivaroxaban in atrial fibrillation increases risk of major bleeding compared to facility preference for apixaban

Event: ESC CONGRESS 2019

Topic: Stroke Prevention

Session: Atrial fibrillation and oral anticoagulation 4

Thumbnail

Non-vitamin K antagonist oral anticoagulants are safe and effective alternatives to warfarin across subgroups by renal function: results from Danish registries

Event: ESC CONGRESS 2019

Topic: Stroke in Atrial Fibrillation

Session: Prevention of thromboembolism and atrial remodelling in atrial fibrillation

Thumbnail

Use of oral anticoagulation and association to outcomes in atrial fibrillation patients who develop chronic kidney disease: a nationwide cohort study

Event: ESC Congress 2018

Topic: Stroke Prevention

Session: Atrial fibrillation - Stroke prevention

Thumbnail

Outcomes in vitamin K antagonist treated atrial fibrillation patients with stable international normalized ratios

Event: ESC CONGRESS 2017

Topic: Atrial fibrillation (AF)

Session: Progress in stroke prevention in atrial fibrillation

Thumbnail

Factors associated with quality of anticoagulation control in patients with atrial fibrillation and risk of stroke and bleeding

Event: ESC CONGRESS 2016

Topic: Atrial fibrillation (AF)

Session: Are you still afraid about bleeding risk of antithrombotic therapy in atrial fibrillation?

Thumbnail

Poor anticoagulation control in warfarin treated atrial fibrillation patients with reduced renal function

Event: ESC CONGRESS 2016

Topic: Atrial fibrillation (AF)

Session: Anticoagulation in atrial fibrillation II

Thumbnail

This platform is supported by

logo Novo Nordisk